MedTrace Logo

Aging and Frailty Study

NCT05268991 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-08-01

No results posted yet for this study

Summary

The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.

Conditions

  • Effects of Chemotherapy
  • Aging
  • Frailty

Interventions

OTHER

Geriatric Assessments and Frailty Indices

Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Heidi Klepin, MD, MS · Wake Forest Baptist Comprehensive Cancer Center

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-02
Primary Completion
2025-06-13
Completion
2025-06-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268991 on ClinicalTrials.gov